Skip to main content
. Author manuscript; available in PMC: 2014 Mar 19.
Published in final edited form as: Am J Transplant. 2013 Aug 22;13(10):2634–2644. doi: 10.1111/ajt.12426

Table 5.

Logistic regression and bootstrap validation of 6-month urinary CXCL9 as a correlate of reaching the GFR endpoint (>30% decrease in eGFR between 6 and 24 months)

n (endpoint+/
endpoint−)		 Parameter estimates
and tests
 ROC-based
discrimination measures
 Positive/negative
predictive value
Model predictors OR (95% CI) p-Value AUC Sensitivity Specificity PPV NPV
23/163 CXCL9 protein 1.929 (1.300, 2.861) 0.0011 0.682 56.5 76.1 25.0 92.5
23/163 CXCL9 protein
GFR		 1.956 (1.314, 2.913)
1.006 (0.985, 1.027)		 0.0010
0.5758		 0.672 60.9 75.5 25.9 93.2
23/163 CXCL9 protein
DSA		 1.933 (1.286, 2.907)
1.033 (0.245, 4.358)		 0.0015
0.9650		 0.687 60.9 74.2 25.0 93.1
23/163 CXCL9 protein
Donor type (deceased)		 1.97 (1.32, 2.96)
2.75 (1.08, 6.96)		 0.0010
0.0335		 0.746 87.0 57.1 22.2 96.9
11/115 CXCL9 protein
Recipient age		 1.94 (1.30, 2.90)
0.97 (0.95, 0.997)		 0.0011
0.0299		 0.711 56.5 69.3 20.6 91.9
10/112 CXCL9 protein
Recipient gender
(female)		 1.97 (1.32, 2.95)
2.29 (0.91, 5.75)		 0.0009
0.0779		 0.721 82.6 46.6 17.9 95.0

AUC, area under the curve; DSA, donor specific antibody; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; ROC, receiver operator characteristics.